BHV3000-302 : Phase 3: Double-Blind, Randomized, Placebo-Controlled, Safety and Efficacy Trial of BHV-3000 (Rimegepant) for the Acute Treatment of Migraine

Trial Profile

BHV3000-302 : Phase 3: Double-Blind, Randomized, Placebo-Controlled, Safety and Efficacy Trial of BHV-3000 (Rimegepant) for the Acute Treatment of Migraine

Recruiting
Phase of Trial: Phase III

Latest Information Update: 09 Aug 2017

At a glance

  • Drugs Rimegepant (Primary)
  • Indications Migraine
  • Focus Therapeutic Use
  • Sponsors Biohaven Pharmaceutical Holding Company
  • Most Recent Events

    • 31 Jul 2017 Status changed from planning to recruiting, according to a Biohaven Pharmaceutical Holding Company media release.
    • 24 Jul 2017 According to a Biohaven Pharmaceutical Holding Company media release, patients in this and another phase 3 study (700286075) will be eligible to participate in a long-term safety study.
    • 24 Jul 2017 According to a Biohaven Pharmaceuticals media release, enrollment is expected to start in summer of 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top